Integrated Quantitative Investments LLC Buys Shares of 4,700 GeneDx Holdings Corp. (NASDAQ:WGS)

Integrated Quantitative Investments LLC bought a new stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 4,700 shares of the company's stock, valued at approximately $361,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. MCF Advisors LLC raised its holdings in GeneDx by 107.7% in the fourth quarter. MCF Advisors LLC now owns 351 shares of the company's stock valued at $27,000 after acquiring an additional 182 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in shares of GeneDx in the 4th quarter valued at $28,000. KLP Kapitalforvaltning AS purchased a new stake in shares of GeneDx during the 4th quarter worth $200,000. Evolution Wealth Advisors LLC acquired a new position in shares of GeneDx during the fourth quarter worth $202,000. Finally, Victory Capital Management Inc. purchased a new position in GeneDx in the fourth quarter valued at $209,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

GeneDx Stock Performance

Shares of WGS stock traded down $6.25 during trading hours on Thursday, hitting $91.04. The stock had a trading volume of 372,580 shares, compared to its average volume of 665,962. The stock's 50 day moving average is $89.49 and its 200 day moving average is $77.32. The firm has a market capitalization of $2.56 billion, a PE ratio of -46.47 and a beta of 1.93. GeneDx Holdings Corp. has a twelve month low of $8.63 and a twelve month high of $115.60. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27.

Remove Ads

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.66. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The company had revenue of $95.64 million for the quarter, compared to the consensus estimate of $82.24 million. As a group, research analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. The Goldman Sachs Group increased their price objective on GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a report on Wednesday, February 19th. TD Cowen raised their price objective on shares of GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $72.33.

Insider Activity

In other news, CFO Kevin Feeley sold 402 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $90.05, for a total value of $36,200.10. Following the completion of the sale, the chief financial officer now directly owns 5,044 shares of the company's stock, valued at $454,212.20. This trade represents a 7.38 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Katherine Stueland sold 10,559 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $96.71, for a total value of $1,021,160.89. Following the completion of the transaction, the chief executive officer now owns 14,865 shares of the company's stock, valued at $1,437,594.15. The trade was a 41.53 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 76,670 shares of company stock valued at $7,301,418. Company insiders own 27.30% of the company's stock.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.